HK Movers | Ascletis Pharma Surges as ASC30 Shows Positive Top-Line Results in 13-Week Phase 2 Obesity Trial

Tiger Newspress12-09

Ascletis Pharma surged 23.3% in Hong Kong.

Ascletis Pharma announced that its 13-week Phase II study (NCT07002905) evaluating the oral small-molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity has achieved positive top-line results. In addition to delivering statistically significant and clinically meaningful weight loss, ASC30 also met its secondary and exploratory endpoints. Across all dose groups, ASC30 reduced multiple established cardiovascular risk markers, including total cholesterol, LDL-C, triglycerides, as well as systolic and diastolic blood pressure. At steady state, ASC30 exposure increased with dose.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111095216?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111095216","market":"hk","top_or_hot":-1,"title":"HK Movers | Ascletis Pharma Surges as ASC30 Shows Positive Top-Line Results in 13-Week Phase 2 Obesity Trial","media":"Tiger Newspress","content":"<html><head></head><body><p>Ascletis Pharma surged 23.3% in Hong Kong.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/98a0cb056558d267330e832564867baa\" tg-width=\"536\" tg-height=\"136\"/></p><p>Ascletis Pharma announced that its 13-week Phase II study (NCT07002905) evaluating the oral small-molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity has achieved positive top-line results. In addition to delivering statistically significant and clinically meaningful weight loss, ASC30 also met its secondary and exploratory endpoints. Across all dose groups, ASC30 reduced multiple established cardiovascular risk markers, including total cholesterol, LDL-C, triglycerides, as well as systolic and diastolic blood pressure. At steady state, ASC30 exposure increased with dose.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Movers | Ascletis Pharma Surges as ASC30 Shows Positive Top-Line Results in 13-Week Phase 2 Obesity Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Movers | Ascletis Pharma Surges as ASC30 Shows Positive Top-Line Results in 13-Week Phase 2 Obesity Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2025-12-09 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Ascletis Pharma surged 23.3% in Hong Kong.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/98a0cb056558d267330e832564867baa\" tg-width=\"536\" tg-height=\"136\"/></p><p>Ascletis Pharma announced that its 13-week Phase II study (NCT07002905) evaluating the oral small-molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity has achieved positive top-line results. In addition to delivering statistically significant and clinically meaningful weight loss, ASC30 also met its secondary and exploratory endpoints. Across all dose groups, ASC30 reduced multiple established cardiovascular risk markers, including total cholesterol, LDL-C, triglycerides, as well as systolic and diastolic blood pressure. At steady state, ASC30 exposure increased with dose.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1111095216","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111095216","pubTimestamp":1765244220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Ascletis Pharma surged 23.3% in Hong Kong.Ascletis Pharma announced that its 13-week Phase II study (NCT07002905) evaluating the oral small-molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"香港推动者|ASC30在为期13周的2期肥胖试验中显示出积极的顶线结果，歌礼制药股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":2},"content_text":"Ascletis Pharma surged 23.3% in Hong Kong.Ascletis Pharma announced that its 13-week Phase II study (NCT07002905) evaluating the oral small-molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity has achieved positive top-line results. In addition to delivering statistically significant and clinically meaningful weight loss, ASC30 also met its secondary and exploratory endpoints. Across all dose groups, ASC30 reduced multiple established cardiovascular risk markers, including total cholesterol, LDL-C, triglycerides, as well as systolic and diastolic blood pressure. At steady state, ASC30 exposure increased with dose.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111095216","isCrawlerRequest":true}